araag2/HINT huggingface dataset:
Clinical trial NCT02052739 (phase 1/phase 2, status: completed)
Conditions: super-refractory status epilepticus
ICD codes: G40.803, G40.804, G40.823, G40.824, G40.833, G40.834, G40.911
Drugs: sage-547
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects 2 years of age and older.

          -  Subjects with an EEG-confirmed SRSE diagnosis under concomitant therapy with a
             continuous IV AED (third-line agent) for ≥ 24 hours. For this study, SRSE is defined
             by the following criteria and in accordance with those used at major epilepsy
             treatment centers:

               -  Failure to respond to the administration of at least one first-line agent (e.g.,
                  benzodiazepine or other emergent initial AED treatment), according to institution
                  standard of care, and

               -  Failure to respond to at least one second-line agent (e.g., phenytoin,
                  fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control
                  AED) according to institution standard of care, and

               -  Presence of one or more breakthrough seizures > 6 hours after initiation of the
                  continuous IV AED/third-line agent (e.g., pentobarbital, midazolam, propofol)

        Exclusion Criteria:

          -  Subjects with SRSE due to anoxic/hypoxic encephalopathy, children (subjects aged less
             than 18 years) with an encephalopathy due to an underlying progressive neurological
             disorder.

          -  Subjects with clinically significant electrocardiogram (ECG) abnormalities.

          -  Subjects with a significant medical or surgical condition that may compromise vital
             organ systems, or other conditions that would place the subject at increased risk such
             as dialysis or acute respiratory distress syndrome, severe cardiogenic or vasodilatory
             shock requiring 2 or more pressors, fulminant hepatic failure, etc.

          -  Subjects who are receiving a continuous IV AED (third-line agent) for seizure
             suppression or burst-suppression that will require greater than 24 hours to wean.
Clinical trial NCT02071537 (phase 1, status: completed)
Conditions: malignant neoplasm, solid tumors
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: chloroquine, carboplatin, gemcitabine
SMILES: CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of a malignancy that is metastatic or unresectable
             and for which either standard curative measures do not exist or are no longer
             effective and carboplatin/gemcitabine is considered a reasonable treatment option
             whether first line or acceptable and approved combination therapy.

          -  Age >18 years of age.

          -  Performance status less than or equal 2 (Karnofsky >60%)

          -  Life expectancy of greater than 3 months.

          -  Adequate labs

          -  Measurable disease

        Exclusion Criteria:

          -  Current treatment with any other investigational agents.

          -  Patients with untreated brain metastases

          -  History of allergic reaction attributed to compounds of similar chemical or biologic
             composition to chloroquine or other agents used in study.
Clinical trial NCT02073123 (phase 1/phase 2, status: completed)
Conditions: metastatic melanoma, stage iii melanoma, stage iv melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: indoximod, ipilimumab, nivolumab, pembrolizumab
SMILES: CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12, COC1=CC=CC=C1OCC(O)CO, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Unresectable Stage III or Stage IV melanoma.

          -  Patients must have measurable disease, defined as lesions that can be accurately
             measure in in 2 perpendicular diameters with at least one diameter > 20mm and the
             other >10mm on conventional CT or MRI or 10mm x 10 mm by spiral CT.

          -  No systemic treatment in the previous 28 days.

          -  Age ≥18 years. Because no dosing or adverse event data are currently available on the
             use of ipilimumab or indoximod in patients <18 years of age, children are excluded
             from this study.

          -  ECOG performance status ≤2 (Karnofsky ≥60% )

          -  Patients with known brain metastases will only be eligible after their tumors have
             been treated with definitive resection and/or radiotherapy and they are neurologically
             stable for at least 1 month off steroids.

        Exclusion Criteria:

          -  Patients who have had molecular targeted therapy (including vemurafenib) or
             radiotherapy within 4 weeks prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.

          -  Patients who have had prior therapy with immune checkpoint inhibition or or indoximod
             are excluded from the trial.

          -  Any other cancer, unless the patient has been disease-free for ≥5 years

          -  Patients with laboratory evidence of pancreatitis are excluded.

          -  Patients with autoimmune disease

          -  Chronic use of immune-suppressive drugs (ie, systemic corticosteroids used in the
             management of cancer or non-cancer related illnesses, eg, COPD).
Clinical trial NCT02077881 (phase 1/phase 2, status: completed)
Conditions: metastatic pancreatic adenocarcinoma, metastatic pancreatic cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C25.3
Drugs: nab-paclitaxel, gemcitabine, indoximod
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has definitive histologically or cytologically confirmed metastatic
             adenocarcinoma of the pancreas. Patients with islet cell or neuroendocrine neoplasms
             are excluded.

          -  Initial diagnosis of metastatic disease must have occurred ≤8 weeks prior to entry in
             the study.

          -  Patient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan ≤4
             weeks prior to entry into the study

          -  Male or non-pregnant and non-lactating female, and ≥18 years of age.

          -  Patients must have received no previous radiotherapy, surgery, chemotherapy or
             investigational therapy for the treatment of metastatic disease.

          -  Prior treatment with gemcitabine and/or nab-paclitaxel in the adjuvant setting is
             allowed, provided at least 6 months have elapsed since completion of the last dose and
             no lingering toxicities are present.

          -  Patients cannot have received any other immunomodulatory therapies (including
             vaccines) as treatment for this or any other cancer.

          -  Patient has a Karnofsky performance status (KPS) ≥ 70.

          -  Patients should be asymptomatic for jaundice prior to Day 1.

        Exclusion Criteria:

          -  Patients may not be receiving (or received prior to enrollment) any other
             investigational agents for metastatic disease.

          -  Patient has known brain metastases,

          -  Patient has only locally advanced disease.

          -  Lymph node only metastases even if considered M1 disease by official staging criteria.

          -  History of malignancy in the last 3 years. Patients with prior history of in situ
             cancer or basal or squamous cell skin cancer are eligible. Patients with other
             malignancies are eligible if they were cured by surgery alone or surgery plus
             radiotherapy and have been continuously disease-free for at least 3 years.

          -  Patients with any active autoimmune disease

          -  Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done
             to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to
             Day 1 of treatment in this study.
Clinical trial NCT02078310 (phase 1/phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: iti-007, placebo, iti-007, placebo
SMILES: [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Part 1

          -  Healthy geriatric volunteers

          -  MMSE score of >= 26 at screening

          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

        Part 2

          -  Geriatric patients with a clinical diagnosis of dementia

          -  MMSE score of < 26 at screening

          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

        Exclusion Criteria:

          -  Any clinically significant illness within 6 months before screening

          -  Any history of cancer within last 5 years

          -  History of Hepatitis B or C infection and elevated ALT, AST or bilirubin above the
             upper limit of normal level

          -  Any subject considered to be an imminent danger to themselves or others
Clinical trial NCT02080195 (phase 1/phase 2, status: terminated)
Conditions: lupus erythematosus, graft-versus-host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: cyclophosphamide, fludarabine, tacrolimus, mycophenolate mofetil, rabbit antithymocyte globulin
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    study was unable to accrue subjects
  
Eligibility criteria:

        Inclusion Criteria:

          -  Four or more American College of Rheumatology (ACR) criteria for the classification of
             SLE or 4 or more of the SLICE criteria

          -  Involvement of one or more of the following organ systems: renal, neurologic,
             hematologic, cardiac, pulmonary, gastrointestinal

          -  A lack of response to corticosteroids in moderate-to-high doses, and to either an
             equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin,
             tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other
             treatment

          -  Patients should be eligible for transplantation according to the BMT Policy Manual

        Exclusion Criteria:

          -  Age less than 18 years and over 75 years

          -  Any risk of pregnancy

          -  Patients who are preterminal or moribund
Clinical trial NCT02080416 (early phase 1, status: terminated)
Conditions: non-hodgkin lymphoma, hodgkin lymphoma, kaposi sarcoma, gastric cancer, nasopharyngeal cancer, ebv, castleman disease
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C46.9, C46.0, C46.2, C46.1, C46.3, C46.4, C46.50, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, A36.1, B87.3, D47.Z2
Drugs: nelfinavir
SMILES: [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
Reason stopped: 
    very slow accrual; terminated to allow resources to be utilized more effectively on other
    studies. no data analysis completed, nor any conclusions reached.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Biopsy proven EBV(+) or KSHV(+) malignancy

          -  Relapsed/refractory disease failing > 2 prior therapies

          -  Measurable, non-bony disease (at least one lesion on radiographic or physical exam
             assessment measuring > 2 cm in longest axis)

          -  KS patients with skin-only disease must have cutaneous lesions amenable to four 3 mm
             punch biopsies during the course of the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status < 2

          -  Life expectancy of greater than 12 weeks

          -  Patients must be able to lie flat for at least 60 minutes and fit on a PET-CT scanner

          -  Ability to comply with an oral drug regimen

          -  Females of childbearing potential must have a negative pregnancy test at screening

          -  Patients must have normal organ and marrow function as defined below within 14 days of
             study entry

        Exclusion Criteria:

          -  Patients with HIV-associated primary central nervous system lymphoma

          -  Radiotherapy or chemotherapy ending within 14 days of study enrollment

          -  Patients currently on other protease inhibitors

          -  Chronic diarrhea

          -  Acute, active infection within 14 days of enrollment

          -  Patients on active treatment for hypo- or hyperthyroidism

          -  End-stage liver disease unrelated to tumor

          -  Hepatitis B or hepatitis C infection

          -  Use of any other type of investigational agent or treatment concurrently or within 28
             days before the first dose of study treatment

          -  History of iodine hypersensitivity

          -  Females who are pregnant or breastfeeding

          -  Physical or psychiatric conditions that in the estimation of the investigator place
             the patient at high risk of toxicity, non-compliance, or inability to complete the
             study requirements

          -  Use of drugs to treat or prevent herpesvirus infections

          -  Essential medication that is known to interact with nelfinavir
Clinical trial NCT02083926 (early phase 1, status: unknown status)
Conditions: social anxiety disorder
ICD codes: F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: ketamine, saline
SMILES: CC1=CC(O)=CC(C)=C1Cl, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult between the ages of 18 and 65 years

          2. Meet DSM IV criteria for Social Anxiety Disorder by structured clinical interview
             (SCID) and have a LSAS >60 with or without co-morbid MDD

        Exclusion Criteria:

          1. Positive pregnancy test

          2. History of substance abuse disorder within the last 6 months or positive urine
             toxicology on screening (within the previous 6 months).

          3. History of pervasive developmental disorder or psychotic disorder by DSM-IV-TR
             criteria

          4. Medical comorbidity that significantly increases the risks associated with ketamine
             infusion (e.g. untreated hypertension, significant cardiovascular disease)
Clinical trial NCT02096601 (phase 1/phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: levodopa and carbidopa sc solution, oral levodopa and carbidopa
SMILES: N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female PD patients of any race aged 30 to 80 years

          2. PD diagnosis consistent with the UK PD Society Brain Bank criteria.

          3. Stable doses of anti PD drugs for at least 30 days

          4. PD patients with well-defined morning "OFF" and a good response to LD

          5. MMSE score > 26

          6. No clinically significant medical, psychiatric or laboratory abnormalities

        Exclusion Criteria:

          1. Atypical or secondary Parkinsonism.

          2. Acute psychosis or hallucinations.

          3. Subjects treated with neuroleptics

          4. History of melanoma or significant skin disorders.

          5. Prior neurosurgical procedure for PD.

          6. Patients with a history of drug abuse or alcoholism

          7. Clinically significant ECG abnormalities.

          8. Renal or liver dysfunction

          9. Subjects who have participated in another clinical study within 30 days
Clinical trial NCT02098629 (phase 1/phase 2, status: withdrawn)
Conditions: myocardial reperfusion injury
ICD codes: I51.5, I25.2, I25.6, I21.9, I21.A1, I21.A9, P29.4
Drugs: milrinone, esmolol, saline infusion
SMILES: CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1, COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1, [Na+].[Cl-]
Reason stopped: 
    difficulty in enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18 years of age or older, who present within 12 hours after the onset
             of chest pain, who has ST-segment elevation of more than 0.1 mV in two contiguous
             leads, and for whom the clinical decision is made to treat with PCI will be eligible
             for enrollment.

        Exclusion Criteria:

          -  Patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, previous
             acute myocardial infarction will not included in the study. Patients with occlusion of
             the left main will be excluded. Patients with baseline heart rate <50 beats/min and
             systolic BP<90 mmHg and pregnant patients will excluded. Finally, patients who have
             any disorder that is associated with immunologic dysfunction (e.g., cancer, lymphoma,
             a positive serologic test for the human immunodeficiency virus, or hepatitis) more
             recently than 6 months before presentation will be excluded.
Clinical trial NCT02100657 (phase 1, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: plitidepsin, bortezomib, dexamethasone
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@H](O)[C@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](CC1=CC=C(OC)C=C1)N(C)C2=O)[C@@H](C)CC)C(C)C, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Prior autologous transplantation (HSCT) patients are allowed.

          -  Patients must have received at least one previous treatment line of induction,
             chemotherapy, chemotherapy and transplantation or previous treatment with bortezomib
             or another proteasome drug

        Exclusion Criteria:

          -  Previous treatment with plitidepsin.

          -  Active or metastatic primary malignancy other than MM.

          -  Serious concomitant systemic disorders

          -  History of hypersensitivity reactions to bortezomib, polyoxyl 35 castor oil or
             mannitol

          -  Neuropathy

          -  Pregnant and/or lactating women

          -  HIV infection

          -  Active hepatitis B or C virus infection.

          -  Treatment with any Investigational Medicinal Product (IMP) in the 30 days before
             inclusion in the study

          -  Plasma cell leukemia at the time of study entry

          -  Contraindication for the use of steroids
Clinical trial NCT02100852 (phase 1, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: tgr-1202 + obinutuzumab + chlorambucil
SMILES: OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed Chronic Lymphocytic Leukemia (CLL)

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

          -  Ability to swallow oral medication

        Exclusion Criteria:

          -  Known hepatitis B virus, hepatitis C virus or HIV infection

          -  Primary central nervous system lymphoma or known intracranial involvement

          -  Autologous hematologic stem cell transplant within 3 months of study entry or
             Allogeneic hematologic stem cell transplant within 12 months
Clinical trial NCT02109341 (phase 1/phase 2, status: completed)
Conditions: metastatic pancreatic cancer
ICD codes: C25.3
Drugs: paclitaxel bound albumine
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  . Males or females ≥ 18 years old and ≤ 75 years old;

          -  Histological or cytological evidence of a diagnosis of pancreatic ductal
             adenocarcinoma;

          -  Written informed consent prior to any study-specific procedures; 4. Measurable
             metastatic disease, defined in according to RECIST Version 1.1 (Eisenhower et al.
             2009), that had not previously been treated with CT for metastatic disease;

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 ;

          -  Absence of previous abdominal radiotherapy on target lesions (except radiation therapy
             analgesic if it has not been performed on measurable targets);

          -  Absence of heart failure or angina or infarction within 12 months previous inclusion;

          -  Have adequate organ function including:

        Hematologic: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L.

        Hepatic: Bilirubin ≤ 1.5 times upper limits of normal (ULN) (Pts may have endoscopic or
        radiologic stenting to treat biliary obstructions).

        Renal: Serum creatinine within normal limits ≤1.5 times ULN.

        Exclusion Criteria:

          -  Age of 76 years or older;

          -  Endocrine or acinar pancreatic carcinoma;

          -  Previous radiotherapy for measurable lesions;

          -  Central nervous system metastasis;

          -  Other concomitant cancer or history of cancer outside a carcinoma in situ of the
             cervix or basal or squamous cell of the skin;

          -  Pts already included in another clinical trial with other experimental drugs;

          -  Current active infection;

          -  Have serious pre-existing medical conditions or serious concomitant systemic disorders
             that would compromise the safety of the patient or his/her ability to complete the
             study, at the discretion of the investigator (for example, unstable angina pectoris,
             or a clinically significant history of cardiac disease or uncontrolled diabetes
             mellitus);

          -  Females who are pregnant or lactating;

          -  Unable to undergo medical test for geographical, social or psychological reason

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency